James D. Brenton

Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company. Provided by Wikipedia
Showing 1 - 10 results of 10 for search 'James D. Brenton', query time: 0.03s Refine Results
  1. 1
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. by David A Tumbarello, Melissa R Andrews, James D Brenton

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients

    Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients by Maria Delgado-Ortet, Maria Delgado-Ortet, Vlad Bura, Vlad Bura, Vlad Bura, Vlad Bura, Ionut-Gabriel Funingana, Ionut-Gabriel Funingana, Ionut-Gabriel Funingana, Ionut-Gabriel Funingana, David Hulse, David Hulse, David Hulse, Leonardo Rundo, Leonardo Rundo, Leonardo Rundo, James D. Brenton, James D. Brenton, James D. Brenton, James D. Brenton, Evis Sala, Evis Sala, Evis Sala, Evis Sala, Evis Sala, Lorena Escudero Sanchez, Lorena Escudero Sanchez

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Phylogenetic quantification of intra-tumour heterogeneity.

    Phylogenetic quantification of intra-tumour heterogeneity. by Roland F Schwarz, Anne Trinh, Botond Sipos, James D Brenton, Nick Goldman, Florian Markowetz

    Published 2014-04-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models

    Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models by Carolin M Sauer, Katrin Heider, Jelena Belic, Samantha E Boyle, James A Hall, Dominique‐Laurent Couturier, Angela An, Aadhitthya Vijayaraghavan, Marika AV Reinius, Karen Hosking, Maria Vias, Nitzan Rosenfeld, James D Brenton

    Published 2022-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.

    Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective... by Christine A Parkinson, Davina Gale, Anna M Piskorz, Heather Biggs, Charlotte Hodgkin, Helen Addley, Sue Freeman, Penelope Moyle, Evis Sala, Karen Sayal, Karen Hosking, Ioannis Gounaris, Mercedes Jimenez-Linan, Helena M Earl, Wendi Qian, Nitzan Rosenfeld, James D Brenton

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

    Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. by Corine M Beaufort, Jean C A Helmijr, Anna M Piskorz, Marlous Hoogstraat, Kirsten Ruigrok-Ritstier, Nicolle Besselink, Muhammed Murtaza, Wilfred F J van IJcken, Anouk A J Heine, Marcel Smid, Marco J Koudijs, James D Brenton, Els M J J Berns, Jozien Helleman

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.

    Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. by Roland F Schwarz, Charlotte K Y Ng, Susanna L Cooke, Scott Newman, Jillian Temple, Anna M Piskorz, Davina Gale, Karen Sayal, Muhammed Murtaza, Peter J Baldwin, Nitzan Rosenfeld, Helena M Earl, Evis Sala, Mercedes Jimenez-Linan, Christine A Parkinson, Florian Markowetz, James D Brenton

    Published 2015-02-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.

    Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. by Lorenza Mittempergher, Anna M Piskorz, Astrid J Bosma, Magali Michaut, G Bea A Wisman, Roelof J C Kluin, Marja Nieuwland, Wim Brugman, Kevin J W van der Ven, Francesco Marass, James Morris, Nitzan Rosenfeld, Mercedes Jimenez-Linan, Steven de Jong, Ate G J van der Zee, James D Brenton, René Bernards

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project

    Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project by Sudha Sundar, Raji Ganesan, Sarah Williams, Joo Ern Ang, Samantha Butler, Janos Balega, Kai Ren Ong, Christine Parkinson, Mercedes Jimenez-Linan, James D Brenton, Parveen Abedin, William Boyle, Lisa Bird, Marie-Lyne Alcaraz, Catherine Spencer, Julie Winning, Elaine Yl Leung, Susan Freeman, Ionut Gabriel Funingana, Anuji Evans, Anna Considine, Kiran Phanasan, Oliver Ridgway, Ian Charles, Rachel Pannell, Jamie Emery, Jayne Salter-Scott

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-13C MRI

    Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-13C MRI by Lucian Beer, Vlad Bura, Stephan Ursprung, Ramona Woitek, Mary A. McLean, Joo Ern Ang, Mercedes Jimenez-Linan, Andrew B. Gill, Joshua Kaggie, Matthew Locke, Amy Frary, Johanna Field-Rayner, Ilse Patterson, Marika Reinius, Martin J. Graves, Surrin Deen, Gabriel Funingana, Leonardo Rundo, Andrew Priest, Luigi Aloj, Roido Manavaki, Iosif A. Mendichovszky, Fraser Robb, Rolf F. Schulte, Dominique-Laurent Couturier, Clive S. D’Santos, Valar Franklin, Kamal Kishore, Iris Allajbeu, Carolin Sauer, Ferdia A. Gallagher, Kevin M. Brindle, James D. Brenton, Evis Sala

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: